Request Demo
Last update 27 Jun 2026
Pembrolizumab Biosimilar(Hualan Genetic Engineering)
Last update 27 Jun 2026
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Pembrolizumab Biosimilar (Hualan Genetic Engineering Co., Ltd.), 帕博利珠单抗生物类似药（华兰基因工程有限公司） |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 93660H
The sequence is quoted from: *****
Sequence Code 93670L
The sequence is quoted from: *****
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Biliary Tract Neoplasms | IND Approval | China | 28 Feb 2026 | |
| Colorectal Cancer | IND Approval | China | 28 Feb 2026 | |
| Esophageal Carcinoma | IND Approval | China | 28 Feb 2026 | |
| Hepatocellular Carcinoma | IND Approval | China | 28 Feb 2026 | |
| Melanoma | IND Approval | China | 28 Feb 2026 | |
| MSI-H/dMMR Solid Tumors | IND Approval | China | 28 Feb 2026 | |
| MSS/MSI-L/pMMR cancer | IND Approval | China | 28 Feb 2026 | |
| Non-Small Cell Lung Cancer | IND Approval | China | 28 Feb 2026 | |
| Squamous Cell Carcinoma of Head and Neck | IND Approval | China | 28 Feb 2026 | |
| Stomach Cancer | IND Approval | China | 28 Feb 2026 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free